Internet Archive Scholar

Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors

Kenichi Matsuzu, Kiminori Sugino, Katsuhiko Masudo, Kazunori Mori, Reiko Ono, Haruhiko Yamazaki, Chie Masaki, Junko Akaishi, Hames Kiyomi Yamada, Chisato Tomoda, Akifumi Suzuki, Takashi Uruno (+5 others)
2020 Endocrine journal  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (980.1 kB)
https://web.archive.org/web/20200504202014/https://www.jstage.jst.go.jp/article/endocrj/advpub/0/advpub_EJ20-0081/_pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL. The file type is application/pdf.

Radioactive iodine (RAI) therapy has been the mainstay of treatment for papillary thyroid carcinoma (PTC) patients with distant metastasis (DM). Although tyrosine kinase inhibitors (TKIs) were introduced for the treatment of RAI refractory metastatic thyroid carcinoma several years ago, clinical outcomes for PTC patients with DM treated using RAI therapy remain unclear. We retrospectively examined 64 PTC patients (9 men, 55 women) with DM at diagnosis treated using RAI therapy without
more » ... tion of any kind of chemotherapy or TKIs. Median age of patients was 58 years. Site of DM was the lungs (n = 59), bone (n = 3), and pleural dissemination (n = 2). No patients showed multiple-organ metastases at diagnosis. By the end of the study period, 21 patients had died of PTC. Cause-specific survival rates at 10, 15, and 20 years after initial surgery were 68.2%, 63.6% and 61.1%, respectively. Uni- and multivariate analyses identified age ≥55 years (HR 3.1, p = 0.023), site of DM other than the lungs (HR 13.4, p < 0.0001), and DM with no RAI avidity (HR 5.1, p = 0.0098) as factors independently associated with disease-related death. When analyses were restricted to patients with lung metastasis (n = 59), surgical non-curability was another independent risk factor (HR 5.2, p = 0.0047) in addition to age and RAI avidity. According to risk stratification analysis based on these risk factors, patients with site of DM other than the lungs or with lung metastasis showing ≥2 risk factors among age ≥55 years, DM with no RAI avidity, and surgical non-curability are expected to show higher mortality rates.
doi:10.1507/endocrj.ej20-0081 pmid:32350192 fatcat:esdg6jcyavau5ehqn2e3pqoete
Open Access
Citation

Kenichi Matsuzu, Kiminori Sugino, Katsuhiko Masudo, Kazunori Mori, Reiko Ono, Haruhiko Yamazaki, Chie Masaki, Junko Akaishi, Hames Kiyomi Yamada, Chisato Tomoda, Akifumi Suzuki, Takashi Uruno, Keiko Ohkuwa, Wataru Kitagawa, Mitsuji Nagahama, Hiroshi Takami, Koichi Ito. "Clinical outcomes and risk stratification for papillary thyroid carcinoma presenting with distant metastasis before the era of tyrosine kinase inhibitors." Endocrine journal 67.8 (2020)